MGNX Rises After Gilead Exercises Option on Bispecific Program
Gilead pays MacroGenics $10 million to license a TRIDENT-based bispecific for solid tumors, extending its cash runway to 2028.
/ 352 items
#XY Event-Driven Stocks↓
Mereo BioPharma Secures Major Option Deal for Alvelestat and Extends Cash Runway
Mereo BioPharma shares rose ~27% after a key option-and-license deal for alvelestat with Sentynl and an updated cash runway into late 2027.
AC Immune’s ACI-7104 Gets FDA Fast Track Designation for Early Parkinson’s Disease
AC Immune’s ACI-7104 receives FDA Fast Track and IND clearance for early Parkinson’s. Phase 2 VacSYn trial can now expand to US sites.
Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.
Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.
Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.